David Malek

David joined NFLS in 2018 and serves as an Investment Director at Pivotal Growth since 2020, responsible for leading new investments at the fund. Prior to joining Pivotal Growth he served as an Operating Partner at Pivotal China, where he was involved in building two new companies: OncXerna and Arctic Vision, and served as their Chief Business Officer. Prior to NFLS, David served as the Chief Business Officer at BioLineRx (NASDAQ: BLRX), where he was responsible for licensing, M&A, strategic alliances and investor relations. During his tenure he built partnerships between BioLineRx and several leading life sciences companies, including Novartis, Genentech and Merck, and led the in-licensing and acquisition of multiple pharmaceutical projects. Prior to his role at BioLineRx David was working for Sanofi in a variety of corporate development, commercial and business development roles in the US and France. David gained his MBA at the Tuck School of Business at Dartmouth and his B.A. in statistics and political science at the University of Haifa.